Intravesical therapy involving bacillus Calmette–Guérin (BCG) is standard of care for high-grade, noninvasive urothelial carcinoma, with reported cure rates higher than 70%. Systemic infection occurs ...
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle ...
Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a ...
A 65-year-old man with a history of T1 high-grade bladder cancer with CIS underwent successful transurethral resection of bladder tumor (TURBT), without residual tumor on second resection. Given his ...
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with ...
Alors que quelque 8000 flacons de BCG Medac sont utilisés chaque mois pour soigner des personnes atteintes d’un cancer de la vessie, seuls 700 flacons étaient disponibles en janvier. Un « tri » s’est ...
(AFP) - Un médicament utilisé pour traiter certains cancers de la vessie, le BCG Medac, va pouvoir être distribué à "l'ensemble des patients concernés en France", après une période de pénurie, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results